Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

BACKGROUND Human papillomavirus types 16 (HPV-16) and 18 (HPV-18) cause approximately 70% of cervical cancers worldwide. A phase 3 trial was conducted to evaluate a quadrivalent vaccine against HPV types 6, 11, 16, and 18 (HPV-6/11/16/18) for the prevention of high-grade cervical lesions associated...

Full description

Autores:

Tipo de recurso:

Fecha de publicación:

2007

Institución:

Universidad del Rosario

Repositorio:

Repositorio EdocUR - U. Rosario

Idioma:

eng

OAI Identifier:

oai:repository.urosario.edu.co:10336/26826

Acceso en línea:

https://doi.org/10.1056/NEJMoa061741
https://repository.urosario.edu.co/handle/10336/26826

Palabra clave:

Hematology
Oncology gynecologic
Oncology dermatology
Vaccines genetics

Rights

License

Abierto (Texto Completo)